The Motley Fool··James HalleyExelixis Expands Beyond Cabozantinib With FDA Approval and Robust Pipeline
Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.
MRKNTRAEXELFDA approvalbiotech